Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Net Cash Flow: 2019-2024

Historic Net Cash Flow for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to $55.4 million.

  • Nurix Therapeutics' Net Cash Flow rose 67.57% to -$5.8 million in Q3 2025 from the same period last year, while for Aug 2025 it was -$20.5 million, marking a year-over-year decrease of 136.20%. This contributed to the annual value of $55.4 million for FY2024, which is 662.30% up from last year.
  • Per Nurix Therapeutics' latest filing, its Net Cash Flow stood at $55.4 million for FY2024, which was up 662.30% from -$9.8 million recorded in FY2023.
  • In the past 5 years, Nurix Therapeutics' Net Cash Flow ranged from a high of $84.5 million in FY2020 and a low of -$38.7 million during FY2021.
  • Over the past 3 years, Nurix Therapeutics' median Net Cash Flow value was -$9.8 million (recorded in 2023), while the average stood at $10.0 million.
  • In the last 5 years, Nurix Therapeutics' Net Cash Flow surged by 816.42% in 2020 and then crashed by 145.82% in 2021.
  • Yearly analysis of 5 years shows Nurix Therapeutics' Net Cash Flow stood at $84.5 million in 2020, then plummeted by 145.82% to -$38.7 million in 2021, then skyrocketed by 60.20% to -$15.4 million in 2022, then surged by 36.13% to -$9.8 million in 2023, then soared by 662.30% to $55.4 million in 2024.